Diclofenac and celecoxib inhibit tumor cell proliferation in a variety of human malignancies and are potential therapeutic drugs targeting glioblastoma cells that work by inhibiting activation of Wnt/β-catenin/Tcf signaling [48]. Here, HNF4A is linked to glioblastoma.